Lenalidomide, a revolutionary drug in the treatment of multiple myeloma, has transformed patient outcomes by enhancing survival rates and improving quality of life. This oral immunomodulatory drug targets cancer cells while boosting the body’s immune response. Key Lenalidomide manufacturers such as Cipla, and Specialitymedz produce high-quality generic versions, making the treatment more accessible globally. By ensuring affordable access to this life-saving medication, these manufacturers play a crucial role in advancing treatment options and providing hope for patients battling multiple myeloma.